← Leaderboards
Edward A Stadtmauer
University Of Pennsylvania
$8,908,337
Attributed
$9,108,678
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $901.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,108,678 · 9
By mechanism
P01$2,634,066 · 1
U01$2,099,423 · 1
UG1$1,810,211 · 1
U10$986,400 · 1
P30$904,490 · 3
R21$400,682 · 1
Top collaborators
- Eline Tjetske Luning Prak2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Bruce J Shenker$14,692,911
- Edward N Pugh$15,475,220
- Aimin Chen$10,063,311
- Stephan A Grupp$7,570,044
- A. Joshua Wand$18,137,286
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical TrialsBone Marrow TransplantationBaseHematologic NeoplasmsInnovationResearch PersonnelProgramsResourcesMalignant - DescriptorAreaMalignant NeoplasmsCellsMemberImmunotherapyCancer CenterMultiple MyelomaChimeric Antigen ReceptorBloodScientistMyeloproliferative DiseaseTranslatingMedical SchoolsFuture
Grant awards (56)
BMT CTN Core- University of Pennsylvania Abramson Cancer Center$239,933
UG1 · FY2025 · HL · contact PI
Hematologic Malignancies Program$81,485
P30 · FY2025 · CA · contact PI
BMT CTN Core- University of Pennsylvania Abramson Cancer Center$243,750
UG1 · FY2024 · HL · contact PI
Hematologic Malignancies Program$83,258
P30 · FY2024 · CA · contact PI
Abramson Cancer Center BMT/CTN Core Clinical Center$193,198
UG1 · FY2023 · HL · contact PI
Hematologic Malignancies Program$83,257
P30 · FY2023 · CA · contact PI
Abramson Cancer Center BMT/CTN Core Clinical Center$193,198
UG1 · FY2022 · HL · contact PI
Hematologic Malignancies Program$84,880
P30 · FY2022 · CA · contact PI
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.$567,040
P01 · FY2021 · CA · contact PI
Abramson Cancer Center BMT/CTN Core Clinical Center$193,198
UG1 · FY2021 · HL · contact PI
Hematologic Malignancies Program$83,107
P30 · FY2021 · CA · contact PI
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.$439,749
P01 · FY2020 · CA · contact PI
Abramson Cancer Center BMT/CTN Core Clinical Center$193,198
UG1 · FY2020 · HL · contact PI
Hematologic Malignancies Research Program$77,523
P30 · FY2020 · CA · contact PI
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.$558,338
P01 · FY2019 · CA · contact PI
Abramson Cancer Center BMT/CTN Core Clinical Center$193,198
UG1 · FY2019 · HL · contact PI
Hematologic Malignancies Research Program$77,593
P30 · FY2019 · CA · contact PI
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.$15,408
P01 · FY2019 · CA · contact PI
Hematologic Malignancies Research Program$7,213
P30 · FY2019 · CA · contact PI
Hematologic Malignancies Research Program$5,768
P30 · FY2019 · CA · contact PI
Hematologic Malignancies Research Program$3,627
P30 · FY2019 · CA · contact PI
Hematologic Malignancies Research Program$1,106
P30 · FY2019 · CA · contact PI
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.$548,256
P01 · FY2018 · CA · contact PI
Abramson Cancer Center BMT/CTN Core Clinical Center$183,538
UG1 · FY2018 · HL · contact PI
Hematologic Malignancies Research Program$155,630
P30 · FY2018 · CA · contact PI
Hematologic Malignancies Research Program$9,404
P30 · FY2018 · CA · contact PI
Hematologic Malignancies Research Program$2,510
P30 · FY2018 · CA · contact PI
Hematologic Malignancies Research Program$2,143
P30 · FY2018 · CA · contact PI
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.$505,275
P01 · FY2017 · CA · contact PI
Abramson Cancer Center BMT/CTN Core Clinical Center$177,000
UG1 · FY2017 · HL · contact PI
Hematologic Malignancies Research Program$73,099
P30 · FY2017 · CA · contact PI
High-throughput immunoglobulin gene sequencing as a peripheral blood minimal residual disease assay to predict post-transplant relapse risk in multiple myeloma$180,930
R21 · FY2016 · CA
Bone Marrow Transplant Clinical Network$165,600
U10 · FY2016 · HL · contact PI
Hematologic Malignancies Research Program$72,887
P30 · FY2016 · CA · contact PI
High-throughput immunoglobulin gene sequencing as a peripheral blood minimal residual disease assay to predict post-transplant relapse risk in multiple myeloma$219,752
R21 · FY2015 · CA
Bone Marrow Transplant Clinical Network$165,600
U10 · FY2015 · HL · contact PI
Bone Marrow Transplant Clinical Network$165,600
U10 · FY2014 · HL · contact PI
Bone Marrow Transplant Clinical Network$165,600
U10 · FY2013 · HL · contact PI
Bone Marrow Transplant Clinical Network$165,600
U10 · FY2012 · HL · contact PI
Bone Marrow Transplant Clinical Network$158,400
U10 · FY2011 · HL · contact PI
Bone marrow transplant clinical network$150,506
U01 · FY2010 · HL · contact PI
Bone marrow transplant clinical network$150,506
U01 · FY2009 · HL · contact PI
Bone marrow transplant clinical network$150,505
U01 · FY2008 · HL · contact PI
Bone marrow transplant clinical network$97,410
U01 · FY2007 · HL · contact PI
Bone marrow transplant clinical network$155,001
U01 · FY2006 · HL · contact PI
Bone Marrow Transplant Clinical Network$30,494
U01 · FY2005 · HL
Bone Marrow Transplant Clinical Network$405,000
U01 · FY2004 · HL
Bone Marrow Transplant Clinical Network$405,000
U01 · FY2003 · HL
Bone Marrow Transplant Clinical Network$150,001
U01 · FY2002 · HL
CMA 676 AS SINGLE AGENT TREATMENT OF PTS WITH ACUTE MYELOID LEUKEMIA$124,146
M01 · FY2002 · RR
Bone Marrow Transplant Clinical Network$405,000
U01 · FY2001 · HL
CMA 676 AS SINGLE AGENT TREATMENT OF PTS WITH ACUTE MYELOID LEUKEMIA$124,146
M01 · FY2001 · RR
CMA 676 AS SINGLE AGENT TREATMENT OF PTS WITH ACUTE MYELOID LEUKEMIA$0
M01 · FY2001 · RR
CMA 676 AS SINGLE AGENT TREATMENT OF PTS WITH ACUTE MYELOID LEUKEMIA$25,114
M01 · FY2000 · RR
CMA 676 AS SINGLE AGENT TREATMENT OF PTS WITH ACUTE MYELOID LEUKEMIA$0
M01 · FY2000 · RR
CMA 676 AS SINGLE AGENT TREATMENT OF PTS WITH ACUTE MYELOID LEUKEMIA$0
M01 · FY2000 · RR